Long-term Survival Outcomes of Prostate Cancer Treated by a Moderately Hypofractionation Regimen (70Gy in 28 fractions): A Single-Center Experience

OBJECTIVE This study aimed to assess the survival outcomes of localized prostate cancer patients treated with moderately hypofractionationated radiation therapy (70Gy in 28 fractions).METHODS Between 2013 and 2018, a total of 96 patients with localized prostate cancer underwent radical radiotherapy. The prescribed dose for the prostate gland was 70Gy delivered in 28 fractions. In cases where elective pelvic lymph node treatment was indicated, the prescribed dose for the elective area was 50.4Gy in 28 fractions. Patient charac-teristics, dose parameters, treatment outcomes, and toxicities were recorded and analyzed. Treatment results were evaluated following the ASTRO-Phoenix recommendations.RESULTS Out of the 96 patients, 86 were eligible for evaluation. The average age of the patients was 74 years, with 73 of the 86 patients (84.9%) categorized as high-risk. Eighty-one of the 86 patients (92.2%) received hormonal treatment. With a median follow-up time of 52 months, the 4-year biochemical control, disease-free survival, and overall survival rates were 100%, 100%, and 91.4%, respectively. Among this cohort, three